Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.44 |
| ▸ | STK4 | Q13043 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | CRHBP | P24387 | 2/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969081 | 0.88 | SRC (0.46) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL16324125 | 0.87 | KDM4E (0.44) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL3426579 | 0.85 | MAP2K1 (0.49) | ALDH1A1HPGD | |
| SCHEMBL1341552 | 0.84 | KDM4E (0.41) | KDM4ESTK4ALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL16803294 | 0.81 | KDM4E (0.39) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL1341502 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1SMN1; SMN2HPGDCSF1R | |
| SCHEMBL1342821 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL19367435 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL22557782 | 0.78 | KDM4E (0.46) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD | |
| SCHEMBL15129379 | 0.77 | KDM4E (0.48) | KDM4EALDH1A1HSD17B10SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689233-B1 | BICYCLIC INHIBITORS OF MEK | ARRAY BIOPHARMA INC (US) | 2012-07-04 | — | — | EP | disclosed |
| US-7772234-B2 | 7-(2,4-Dichlorophenylamino)-8-fluoro-4-methyl-cinnoline-6-carboxylic acid (2-hydroxyethoxy)-amide; mitogen activated protein, extracellular signal regulated kinase, kinase inhibitor; cancer and inflammation | ARRAY BIOPHARMA INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1689233-A4 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1689233-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | ARRAY BIOPHARMA INC. | 2005-06-16 | — | — | US | disclosed |
| WO-2005051302-A2 | BICYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050130976-A1 | Bicyclic inhibitors of MEK and methods of use thereof | NRAS, BRAF, RAF1 | KDM4E 960/4885STK4 1014/4885ALDH1A1 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.